On November 20, the United States Patent and Trademark Office (USPTO) issued a final rule adjusting patent fees beginning in 2025. According to the Office, the new fee schedule will increase fee collections by approximately...more
By now you have seen multiple reports discussing the PTO’s Notice of July 29, 2022, relating to the duties of candor and good faith. Federal Register, Vol. 87, No. 145, July 29, 2022....more
9/16/2022
/ Duty of Candor ,
Food and Drug Administration (FDA) ,
Good Faith ,
Life Sciences ,
Medical Devices ,
New Guidance ,
Orange Book ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
USPTO
Fish and Richardson has obtained the first appellate reversal of a Post-Grant Review (PGR) proceeding at the United States Court of Appeals for the Federal Circuit since the proceedings were first implemented in...more
On October 27, the PTAB issued a Final Written Decision in an IPR challenging claims 1-8 of US Patent 8,337,856, directed to immunoconjugates comprising an anti-ErbB antibody, such as the humanized anti-ErbB2 antibody known...more